Search clinical trials for: Interleukin-2 (Aldesleukin)

Total 16783 results

University Hospital, Bordeaux

Completed

Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (ANEMIL)

Autoimmune Hemolytic Anemia

France
City of Hope Medical Center

Completed

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Glioblastoma | Brain Tumor | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Giant Cell Glioblastoma | Anaplastic Meningioma | Mixed Glioma | Brain Stem Glioma | Ependymoblastoma | Grade III Meningioma | Meningeal Hemangiopericytoma | Pineal Gland Astrocytoma

United States
Scott B. Snapper, MD PHD

Completed

Low Dose IL-2 for Ulcerative Colitis

Ulcerative Colitis

United States
Anil K. Chandraker, MD

Terminated

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation

Kidney Transplantation

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States
Boston Children's Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Recruiting

Low Dose IL-2 for the Treatment of Crohn's Disease

Crohn Disease

United States
Case Western Reserve University

Terminated

HIV Reservoir Reduction With Interleukin-2 (IL2)

HIV Infection

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

Leukemia

United States, Switzerland, Canada, Netherlands, Puerto Rico, Australia
National Institute of Allergy and Infectious Diseases...
ANRS, Emerging Infectious Diseases

Completed

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx (ILIADE)

HIV Infections

United States, France
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH); Chiron...

Completed

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Kidney Cancer

United States
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma

United States
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis Fungoides/Sezary Syndrome | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Mycosis Fungoides/Sezary Syndrome | Stage I... and other conditions

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Virginia
National Cancer Institute (NCI)

Unknown

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Liu Tian

Recruiting

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Centre Hospitalier Universitaire de Nīmes

Completed

Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 (IMODALS)

Amyotrophic Lateral Sclerosis

France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Gregory Knapp

Not yet recruiting

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Triple Negative Breast Cancer
Carman Giacomantonio
Nova Scotia Health Authority

Withdrawn

The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

Cutaneous Metastatic Melanoma
National Institute of Allergy and Infectious Diseases...
Chiron Corporation

Completed

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy (ESPRIT)

HIV Infections

United States, Brazil, Australia, Argentina, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Morocco, Netherlands, Norway, Poland, Portugal, Singapore, Spain, Sweden, Switzerland, Thailand, United Kingdom
Peking University People's Hospital

Recruiting

Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Second Xiangya Hospital of Central South University

Not yet recruiting

Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

China
Tanta University

Completed

IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients

Covid19

Egypt
Sumithira Vasu

Completed

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
National Cancer Institute (NCI)

Completed

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
PACT Pharma, Inc.

Suspended

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Solid Tumor

United States
The First Hospital of Jilin University

Completed

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases (SLE，pSS，JIA)

Systemic Lupus Erythematosus

China
Peking University People's Hospital

Unknown

Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy

Inflammatory Myopathy
Peking University People's Hospital

Unknown

Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica

Polymyalgia Rheumatica
Peking University People's Hospital

Unknown

Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）

Macrophage Activation Syndrome

China
Fred Hutchinson Cancer Center

Completed

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Peking University People's Hospital

Enrolling by invitation

Interleukin-2 on Active Dermatomyositis

Dermatomyositis

China
University Hospital Tuebingen

Completed

Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases

Melanoma

Germany
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
Peking University People's Hospital

Completed

Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis

Relapsing Polychondritis

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | EBV-Positive Neoplastic Cells Present | HLA-A*0201 Positive Cells Present | Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Elevated WT1

United States
Second Xiangya Hospital of Central South University

Recruiting

Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris

Pemphigus Vulgaris

China
Cambridge University Hospitals NHS Foundation Trust

Completed

Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY (IVORY)

Acute Coronary Syndromes

United Kingdom
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

High Risk Non-Hodgkin's Lymphoma

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial (ACTIVATE)

Advanced Ovarian Cancer | Malignant Melanoma

Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Stage IV Melanoma

United States
Jay S. Skyler
University of Florida; University of California, San Francisco; Diabetes Research...

Withdrawn

Low-dose IL-2 in Established T1D - The "PROREG" Study

Diabetes | Diabetes Mellitus, Type 1 | Diabetes, Autoimmune

United States
Peking University People's Hospital

Recruiting

Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome

Sjögren's Syndrome

China
Northwestern University
National Cancer Institute (NCI)

Completed

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Kidney Cancer

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States

Search clinical trials for: Interleukin-2 (Aldesleukin)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations